rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-4-604-605rpcardio-512Research ArticleFROM THE JACCИЗ JACCCOMMENTS TO THE PAPER «RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS»КОММЕНТАРИИ К СТАТЬЕ «РАМИПРИЛ ПОВЫШАЕТ ЧУВСТВИТЕЛЬНОСТЬ ТРОМБОЦИТОВ К ОКСИДУ АЗОТА. ЗНАЧЕНИЕ ЭТОГО ФЕНОМЕНА ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С ВЫСОКИМ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ»(RAMIPRIL SENSITIZES PLATELETS TO NITRIC OXIDE IMPLICATIONS FOR THERAPY IN HIGH-RISK PATIENTS)НебиеридзеД. В.NebieridzeD. V.
д.м.н., профессор, руководитель отдела профилактики метаболических нарушений
dneberidze@gnicpm.ruГосударственный научно-исследовательский центр профилактической медициныRussian Federation20120201201684604605Copyright © Nebieridze D.V., 20152015Небиеридзе Д.В.Nebieridze D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/512
.
ReferencesNational guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр) Системные гипертензии 2010; (3): 5–26).National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр) Системные гипертензии 2010; (3): 5–26).National guidelines for diagnosis and treatment of chronic heart failure (second revision). Serdechnaya nedostatochnost' 2006; 8(2): 1–35. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердечная недостаточность 2006; 8(2): 1–35).National guidelines for diagnosis and treatment of chronic heart failure (second revision). Serdechnaya nedostatochnost' 2006; 8(2): 1–35. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (второй пересмотр). Сердечная недостаточность 2006; 8(2): 1–35).НOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor , ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.НOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor , ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–788.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–788.Bonner G, Preis S, Schunck U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (suppl 6): 46–56.Bonner G, Preis S, Schunck U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (suppl 6): 46–56.Busse R, Lamontagne D. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn–Schmiede-bergs Arch Pharmacol 1991; 344:126–9.Busse R, Lamontagne D. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn–Schmiede-bergs Arch Pharmacol 1991; 344:126–9.Lonn E.M., Yusuf S., Dzavic V . et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation 2001:103:919–25.Lonn E.M., Yusuf S., Dzavic V . et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation 2001:103:919–25.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–87.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–87.Chirkov Y .Y ., Holmes A.S., Willoughby S.R., et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 2001;37:1851–7.Chirkov Y .Y ., Holmes A.S., Willoughby S.R., et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 2001;37:1851–7.Anfossi G., Russo I., Massucco P ., et al. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects. Thromb Res 2003; 110: 39–46.Anfossi G., Russo I., Massucco P ., et al. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects. Thromb Res 2003; 110: 39–46.Willoughby S.R., Rajendran S., Chan W.P . Ramipril Sensitizes Platelets to Nitric Oxide: Implications for Therapy in High-Risk Patients. J Am Coll Cardiol 2012 May 23 [Epub ahead of print].Willoughby S.R., Rajendran S., Chan W.P . Ramipril Sensitizes Platelets to Nitric Oxide: Implications for Therapy in High-Risk Patients. J Am Coll Cardiol 2012 May 23 [Epub ahead of print].
The authors declare that there are no conflicts of interest present.